同和药业：近日收到国家知识产权局颁发的发明专利证书

Group 1 - The core point of the article is that Tonghe Pharmaceutical has received a patent for a new intermediate related to Resmetirom, which may enhance its product offerings and market position [1] - The company reported that for the first half of 2025, its revenue composition is heavily weighted towards pharmaceutical manufacturing, accounting for 99.51% of total revenue, with other businesses contributing only 0.49% [1] - As of the report date, Tonghe Pharmaceutical has a market capitalization of 3.7 billion yuan [1]